-
Seven drug types of the market is rising, Panlong Pharmaceutical is facing raw material bottlenecks!
Time of Update: 2022-11-26
On the evening of October 27, Shaanxi Panlong Pharmaceutical Group Co. , Ltd. (Panlong Pharmaceutical, 002864. SZ) disclosed that the third quarter report of 2022 showed that in the first three quart
-
The market prospect of new drugs for renal anemia is considerable, and domestic pharmaceutical companies are actively layout
Time of Update: 2022-11-26
In addition to tablets, Dongguang Pharmaceutical also has self-developed class 1 new drug HEC53856 capsules intended for the treatment of anemia associated with chronic kidney disease, including dialysis and non-dialysis patients.
-
When benefit-risk assessment becomes the focus, a new round of supply-side reform of innovative drugs begins
Time of Update: 2022-11-26
According to the Draft Opinion, the marketing application of innovative drugs: the benefits of drugs – risk assessment is a key process in regulatory decision-making, which ultimately determines whether it is approved.
-
MYVACET™ 9-45 Diacetylmonoglycerides registration number has been activated to "A" status!
Time of Update: 2022-11-26
Used in creams and ointments Diacetylmonoglycerides provide moisture protection At present, in addition to rabeprazole sodium enteric-coated tablets, colaveram hydrochloride tablets, sevelamam hydrochloride tablets, sodium valproate enteric-coated tablets, erythromycin enteric-coated tablets and other varieties have used diacetylmonoglycerides.
-
How to view inter-provincial tourism operation activities is no longer linked with risk areas to implement linkage management
Time of Update: 2022-11-26
On November 15, the Ministry of Culture and Tourism issued a notice on further optimizing the prevention and control measures of the new crown pneumonia epidemic, scientifically and accurately doing a good job in the prevention and control of the cultural and tourism industry, proposing that cross-provincial tourism business activities will no longer implement linkage management with risk areas, and increase the "one-size-fits-all" and layer-by-layer rectification of problems.
-
Latest! CDE Releases New Regulations for Dissolution Curve Research!
Time of Update: 2022-11-26
Annex: Q&A on dissolution curve research of "Technical Guidelines for the Study of Pharmaceutical Changes of Listed Chemicals (Trial)" Drug Review Center, State Food and Drug Administration November 7, 2022 Related attachments serial number Attachment name 1 Q&A .
-
State Food and Drug Administration: Solidly promote the landing and production of key foreign-funded pharmaceutical projects
Time of Update: 2022-11-26
drugsmedical devicesforeign-funded pharmaceutical First, in accordance with the requirements of the relevant notice on strengthening the service work of foreign-funded enterprises, we will continue to promote the implementation of various work and achieve results.
-
The Autumn Exhibition, this experimental analysis instrument [Summit Forum] should not be missed
Time of Update: 2022-11-26
@All Instrument People On November 15, the "2022 Video Fair Autumn Exhibition" online exhibition hosted by Instrument Network was grandly opened. Nearly 100 enterprises actively participated in the ex
-
National Health Commission: The state has not adjusted the diagnostic criteria for adult hypertension
Time of Update: 2022-11-26
standards Regarding the diagnostic criteria for hypertension, in 2005, 2010 and 2017, the national health administrative department issued publicity and education points, prevention and treatment guidelines, clinical pathways, etc.
-
2022 Video Conference Autumn Exhibition, these three [Cloud Interview] live broadcasts must not be missed!
Time of Update: 2022-11-26
to better understand corporate brands, products, technologies and purchase good instrumentation products, this online exhibition will last until November 21 。 Click on the picture to watch the opening ceremony Online exhibition hall, cloud interview, summit forum, live selection, procurement hall.
-
Notice on the public solicitation of comments on the "New Drug Benefits - Technical Guidelines for Risk Assessment"
Time of Update: 2022-11-26
Notice on the public solicitation of comments on the "New Drug Benefits - Technical Guidelines for Risk Assessment" Release date: 20221108 In order to further standardize and guide the benefit-risk assessment in the clinical development and evaluation of drugs, and provide technical specifications for reference, our center drafted the "New Drug Benefit-Risk Assessment Technical Guidelines", which has been discussed within the center and formed a draft for comments.
-
The Ministry of Finance has invested more than 26.5 billion yuan in medical infrastructure! A new round of pharmaceutical procurement is rising!
Time of Update: 2022-11-26
On November 17, the medical device sector was still relatively active, and Huangshan capsules were up and down intraday, and they had closed 3 consecutive limit plates; Aipeng Medical closed up 14. 2
-
BeiGene starts overtaking in a corner? National talks are coming, domestic PD-1 commercialization competition!
Time of Update: 2022-11-26
For the PD-1 monoclonal antibody "domestic tigers" of Innovent Biologics, Hengrui Pharmaceutical, BeiGene, and Junshi Biologics, which have long been included in medical insurance, the highlight of this year's medical insurance negotiations is to see the competition for new indications into medical insurance.
-
Under the favorable policy, domestic pharmaceutical companies began to focus on the research and development of children's anti-tumor drugs
Time of Update: 2022-11-26
js?cdnversion='+~(-new Date()/36e5)];Recently, CDE issued a notice to publicly solicit opinions on the "Technical Guidelines for Clinical R&D of Children's Antineoplastic Drugs", which covers four major chapters, including background, overall considerations for clinical R&D of pediatric antineoplastic drugs, clinical R&D paths for pediatric antineoplastic drugs, and issues requiring special attention, and the time limit for soliciting comments is 1 month from the date of issuance.
-
Under the accelerated internationalization of local pharmaceutical companies, another domestic PD-1 product applied for going overseas!
Time of Update: 2022-11-26
Teripulimab is an anti-PD-1 monoclonal antibody drug independently developed by Junshi Biologics, and the submission of the marketing authorization application (MAA) to EMA means that after China and the United States, the global commercialization of teripulimab has begun to expand to Europe.
-
Under the high prosperity of China's API industry, there is good news recently
Time of Update: 2022-11-26
js?cdnversion='+~(-new Date()/36e5)];China is a major producer and exporter of APIs, with the continuous expansion of the pharmaceutical market, APIs as the basic raw materials for drug production, the market scale is increasing year by year, and the layout of related pharmaceutical companies in products is also accelerating.
-
Do not "fill in the blanks" for the decline in the proportion of drugs, and change the price of medical services to the same frequency as residents' income
Time of Update: 2022-11-26
criteriaof drugs Compared with the two programs, the increase in income generated by social and economic development is undoubtedly the resource space for medical service price reform.
-
$2.8 billion in large varieties to meet the fierce enemy, Huahai, Dongguang Medicine... 63 ANDAs were acquired
Time of Update: 2022-11-26
com From the perspective of the number of ANDA approvals in recent years, it reached the highest level in 2017, and the policy of "going overseas and reporting to China" has increased the speed of approval of relevant generic drugs in China, which will help domestic pharmaceutical companies quickly seize the market.
-
Industry: The performance of APIs has begun to show an inflection point, and it is expected to achieve high growth
Time of Update: 2022-11-26
js?cdnversion='+~(-new Date()/36e5)];In the first three quarters of 2022, affected by factors such as the environment and the sharp increase in raw material prices, the overall performance of listed API companies was under obvious pressure, and the general increase in revenue did not increase profits.
-
Latest! EMA regulatory strategy adjustment for pharmaceutical nitrosamine impurities
Time of Update: 2022-11-26
Question 10: Upper limit of nitrosamine impurities in pharmaceutical products Two new nitrosamine compounds, 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NKK), and N-nitrosoyl, are added to the document table, and the corresponding ADI (Acceptable Daily Intake) is specified Allowable daily intake) The limit is 100 ng/day.
